Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Diverse Clinical Presentations of C3 Dominant Glomerulonephritis
Ramy M. Hanna
, Jean Hou
, Huma Hasnain
, Farid Arman
, Umut Selamet
, James Wilson
, Samuel Olanrewaju
, Jonathan E. Zuckerman
, Marina Barsoum
, Julie M. Yabu
, Ira Kurtz
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Diverse Clinical Presentations of C3 Dominant Glomerulonephritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Presentation
100%
Pauci-immune Glomerulonephritis
100%
Glomerulonephritis
100%
C3 Glomerulopathy
62%
Older Women
37%
Dense Deposit Disease
25%
Transplantation
12%
Endothelial Cell Damage
12%
Dysregulation
12%
Treatment Options
12%
Genetic Testing
12%
Clinical Course
12%
Pathogenic Mechanism
12%
Alternative Complement Pathway
12%
Emerging Treatments
12%
Treatment Course
12%
Phenotypic Variation
12%
Peri
12%
Biopsy Diagnosis
12%
Initial Biopsy
12%
Regulatory Factors
12%
Complement Activation
12%
Immunofluorescence Staining
12%
Glomerular Injury
12%
Crescentic Glomerulonephritis
12%
Membranoproliferative
12%
Anti-factor H Antibody
12%
Complement Gene mutations
12%
Medicine and Dentistry
Glomerulonephritis
100%
Antigen Antibody Complex
100%
Membranoproliferative Glomerulonephritis
100%
Glomerulopathy
50%
Biopsy Technique
37%
Diseases
25%
Endothelial Cell
12%
Cell Damage
12%
Immunofluorescence
12%
Disease Course
12%
Emerging Treatment
12%
Genetic Screening
12%
Complement Alternative Pathway
12%
Complement Activation
12%
Complement Factor H
12%
Phenotypic Variation
12%
Treatment Option
12%
Immunology and Microbiology
Glomerulonephritis
100%
Immune Complex
72%
Staining
18%
Cell Damage
9%
Genetic Screening
9%
Immunofluorescence
9%
Alternative Complement Pathway
9%
Complement Activation
9%
Phenotypic Variation
9%
Factor H
9%
Endothelial Cells
9%